Amanda Oswalt
Family · Hermann, MONPI 1710175815
Payments from drug & device makers
Across 84 payments — averaging $45.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$3K
- Lilly USA, LLC$292
- Novo Nordisk$146
- Otsuka America Pharmaceutical, Inc.$84
- AbbVie$81
- Dexcom, Inc.$81
- plus $572 from 19 others
What the payments were for
- Speaking & faculty fees$1,62542%
- Travel & lodging$91124%
- Food & beverage$1,32234%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 8 | $2,603 |
| Lilly USA, LLC | 19 | $292 |
| Novo Nordisk | 9 | $146 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| AbbVie | 4 | $81 |
| Dexcom, Inc. | 3 | $81 |
| Exact Sciences | 4 | $69 |
| Medtronic | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Abbott | 3 | $43 |
| Boehringer Ingelheim | 3 | $43 |
| Bayer | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Merck | 2 | $29 |
| Sumitomo Pharma America, Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Pfizer | 1 | $18 |
| Averitas Pharma Inc. | 1 | $18 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $15 |
| Insulet Corporation | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Rhythm Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE HYPOPEN$2,376
How this compares
$3,859 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $187,744 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 105 | $97,921 |
| MounjaroTirzepatide | 65 | $84,511 |
| Humalog Kwikpen U-200Insulin Lispro | 28 | $70,440 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $54,502 |
| JardianceEmpagliflozin | 42 | $45,581 |
| TrulicityDulaglutide | 25 | $33,432 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $31,777 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $24,269 |
| Gvoke Hypopen 2-PackGlucagon | 34 | $20,570 |
| FarxigaDapagliflozin Propanediol | 22 | $20,528 |
| RybelsusSemaglutide | 12 | $20,283 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $12,680 |
| Novolog FlexpenInsulin Aspart | 25 | $10,351 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $10,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $146 | $208,027132 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $292 | $134,904165 claims |
| Boehringer IngelheimJardiance | $43 | $45,58142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Hermann
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.